Opioid pharmaceutical boss guilty of scheme which bribed doctors to prescribe painkillers
Posted May 03, 2019 11:37:12
The founder of Insys Therapeutics is the highest-ranking pharmaceutical executive to be convicted in a case tied to the US opioid crisis, after he and four colleagues were found guilty of participating in a scheme to bribe doctors to prescribe an addictive painkiller.
- Insys makes the fentanyl spray Subsys, which is used to treat severe cancer pain
- Fentanyl is an especially potent opioid, 100 times stronger than morphine
- Kapoor was found guilty of running a scheme to bribe doctors and for misleading insurers about paying for the drug
A federal jury in Boston found John Kapoor, the drugmaker’s former chairman, and his co-defendants guilty of racketeering conspiracy for engaging in a scheme that also misled insurers into paying for the drug.
Kapoor’s 2017 arrest came on the same day US President Donald Trump declared the epidemic, that has caused tens of thousands of overdose deaths annually, a public health emergency.
Kapoor, 76, was found guilty of running a wide-ranging scheme to bribe doctors across the US by retaining them to act as speakers at sham events at restaurants, ostensibly meant to educate clinicians about its fentanyl spray, Subsys.
Prosecutors said Kapoor also directed efforts to defraud insurers who were reluctant to pay for Subsys.
His co-defendants were former Insys executives and managers Michael Gurry, Richard Simon, Sunrise Lee and Joseph Rowan.
They face up to 20 years in prison. They denied wrongdoing, and defence lawyers signalled plans to appeal.
“Dr Kapoor is disappointed in the verdict, as are we,” Beth Wilkinson, Kapoor’s lead attorney, said in a statement.
“Four weeks of jury deliberations confirm that this was far from an open-and-shut case.”
The US Food and Drug Administration approved Subsys in 2012 only for use in treating severe cancer pain.
Yet prosecutors claimed doctors who took bribes often prescribed Subsys to patients without cancer, helping boost sales for the Arizona-based Insys.
Fentanyl is an especially potent opioid, 100 times stronger than morphine.
Kapoor’s lawyers acknowledged Insys paid doctors but contended he believed they were being legally paid to discuss Subsys’ benefits.
Ms Wilkinson, in her opening statement in January, told jurors Kapoor had no knowledge of “side deals” being cut with doctors.
She said a former executive-turned-government-witness, Alec Burlakoff, kept Kapoor in the dark about them.
Mr Burlakoff, Insys’ ex-vice president of sales, and Michael Babich, its former chief executive, testified against Kapoor after pleading guilty to participating in the scheme.
Jurors during the trial watched a rap video Insys produced for its sales staff describing its strategies to boost sales that starred Mr Burlakoff dressed as a dancing bottle of Subsys.
Witnesses also testified that Lee, an ex-stripper turned Insys regional sales director, gave a lap dance to a doctor at a Chicago club while pushing him to prescribe Subsys.
Insys in August said it had agreed to pay at least $US150 million ($214 million) in a related settlement with the US Justice Department.
In a statement in reaction, the company said the case involved “the actions of a select few former employees”.